Location History:
- Bethesda, MD (US) (2013)
- Antony, FR (2012 - 2016)
Company Filing History:
Years Active: 2012-2016
Title: Innovations by Lydie Cassard: Pioneering T Cell Receptor Technologies
Introduction
Lydie Cassard, an esteemed inventor based in Antony, France, has made significant contributions to the field of immunology through her innovative research and patent developments. With a total of three patents to her name, she has carved out a notable niche in the fight against cancer, particularly by exploring the potential of T cell receptors.
Latest Patents
One of her latest patents involves the development of GP100-specific T cell receptors and related materials and methods of use. This groundbreaking invention focuses on human T cells that incorporate a murine T Cell Receptor (TCR) specific to the cancer antigen gp100. Her research provides isolated or purified TCRs with specificity for particular amino acids of gp100, along with related polypeptides, proteins, nucleic acids, recombinant expression vectors, and various pharmaceutical compositions. Notably, this innovation outlines methods for detecting the presence of cancer in a host, as well as approaches for treating or preventing cancer using these inventive materials.
Career Highlights
Lydie works for the Government of the United States of America as represented by the Secretary of the Department of Health and Human Services. Her research and development efforts have positioned her as a key player in advancing cancer treatment technologies.
Collaborations
Throughout her career, Lydie Cassard has collaborated with prominent figures in the field, including Nicholas P Restifo and Zhiya Yu. These partnerships have enhanced her research endeavors and fostered a collaborative spirit within the scientific community.
Conclusion
Lydie Cassard’s contributions to the field of cancer treatment through her innovative patents underscore her role as a leading inventor. Her work not only aids in the detection and treatment of cancer but also showcases the potential for T cell receptor technologies to transform therapeutic approaches in oncology.